Brian Casey and Wayne Forrest[email protected]Clinical NewsPull linear MRI contrast from market, European group saysIn a stunning development, a European Union regulatory body on Friday recommended that four gadolinium-based contrast agents for MRI scans be pulled off the market due to concerns about gadolinium remaining in the body years after scans occur. The agents affected include some of the most widely used contrast products in medical imaging.March 9, 2017Page 1 of 1Top StoriesNuclear MedicineLu-177 PNT2002 before SBRT extends disease control in prostate cancerA group from the University of California, Los Angeles, updated an analysis of outcomes from the LUNAR trial by 10 months.MRIAI on par with radiologists for finding prostate cancer on MRICTJFR: Radiologists, urologists, and patients collaborate for kidney tumor treatmentPartner ContentBayer’s Joana Reis: Breast screening moves beyond one-size-fits-allPartner ContentBehind the scan: From warehouse to patient in Maastricht